The serum level of HMGB1 in patients with nonsmall cell lung cancer (NSCLC) was significantly higher compared to patients with chronic obstructive pulmonary disease, suggesting that HMGB1 may be a useful marker for evaluating NSCLC progression [70]. Here, HMGB1 is linked to chronic obstructive pulmonary disease.